Story perspectives

FDA Launches Fast-Track Pathway for Personalized Rare Disease Treatments

2/23/2026

Summary

Story summary

The FDA announced a new regulatory pathway on February 23, 2026, to facilitate personalized medicines for ultra-rare diseases.
This initiative allows drugmakers to bypass traditional clinical trials for small patient groups by justifying the absence of randomized trials and collecting real-world evidence post-approval.
Health Secretary Robert F. Kennedy Jr. emphasized the initiative's urgency, referencing a successful gene editing therapy for an infant as a catalyst for change.
The FDA will accept public comments on the draft guidance for 60 days.

1 of 1

Story summary

The FDA announced a new regulatory pathway on February 23, 2026, to facilitate personalized medicines for ultra-rare diseases.
This initiative allows drugmakers to bypass traditional clinical trials for small patient groups by justifying the absence of randomized trials and collecting real-world evidence post-approval.
Health Secretary Robert F. Kennedy Jr. emphasized the initiative's urgency, referencing a successful gene editing therapy for an infant as a catalyst for change.
The FDA will accept public comments on the draft guidance for 60 days.